Condition: Tumor Hyperinsulinism (Tumor HI) · Sponsor: Rezolute
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
This description comes directly from the study's public registry record.
Rezolute Clinical Trial · 650-206-4507 · clinicaltrials@rezolutebio.com
Always discuss trial participation with your own doctor first.
| Investigative Site | Chicago, Illinois, United States | Recruiting |
| Investigative Site | Bethesda, Maryland, United States | Not Yet Recruiting |
| Investigative Site | Boston, Massachusetts, United States | Recruiting |
| Investigative Site | Rochester, Minnesota, United States | Recruiting |
| Investigative Site | New York, New York, United States | Recruiting |
| Investigative Site | Canton, Ohio, United States | Recruiting |
| Investigative Site | Portland, Oregon, United States | Recruiting |
| Investigative Site | Houston, Texas, United States | Not Yet Recruiting |
| Investigative Site | Clichy, Île-de-France Region, France | Recruiting |
| Investigative Site | Rotterdam, South Holland, Netherlands | Recruiting |
| Investigative Site | Basel, Canton Basel-Stadt, Switzerland | Recruiting |
| Investigative Site | Saint Johns Wood, London, United Kingdom | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06881992